Women with hereditary non-polyposis colorectal cancer (HNPCC) have a 40-60% risk for developing endometrial cancer. We are studying agents which may decrease the risk of endometrial cancer. Oral contraceptives and progestins have been shown to decrease the risk of endometrial cancer. The two study drugs used in this clinical research trial are the oral contraceptive agent LoOvral and the injectable contraceptive depoProvera. Both of the study drugs are standard approved contraceptive methods. The goal of this randomized clinical research study is to study the effects of these agents on the endometrial lining in women with HNPCC after three months of using the oral contraceptive LoOvral or depoMPA. The total length of participation in this study is 12-14 weeks. Women with a known mutation, between the age of 30-50 are eligible for this study. Funds are available for genetic testing and travel expenses. This is an NCI/DCP funded study (N01-CN-05127).

Share This